XML 50 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
NeuVaxTM Acquisition (Tables)
 12 Months Ended
Dec. 31, 2013
Business Combinations [Abstract]  
Purchase Price Consideration and Allocation of Purchase Price
The purchase price consideration and allocation of purchase price were as follows (in thousands):
Calculation of allocable purchase price:
 
 
 
 
Fair value of shares issued at closing including escrowed shares expected to be released
 
$
6,367

 
(i)
Estimated value of earn-out
 
6,460

 
  
Total allocable purchase price
 
$
12,827

 
  
Allocation of purchase price:
 
 
 
 
Cash
 
$
168

 
  
Prepaid expenses and other current assets
 
14

 
  
Equipment and furnishings
 
11

 
  
Goodwill
 
5,898

 
  
In-process research and development
 
12,864

 
  
Accounts payable
 
(931
)
 
 
Accrued expenses and other current liabilities
 
(143
)
 
 
Notes payable
 
(1
)
 
 
Deferred tax liability, non-current
 
(5,053
)
 
 
 
 
$
12,827

 
  
 
(i)
The value of the company’s common stock was based upon a per share value of $1.28, the closing price of the company’s common stock as of the close of business on April 13, 2011.
Pro Forma Net Loss and Pro Forma Net Loss Per Common Share
The following presents the unaudited, pro forma net loss and pro forma net loss per common share of the company for year ended December 31, 2011 as if the company’s acquisition of Apthera occurred as of January 1, 2011 (in thousands expect for per share data):
 
 
For the Year Ended
December 31, 2011
Net loss from continuing operations
$
(4,700
)
Net loss from discontinued operations
$
(8,078
)
Net loss per common share, continuing operations
$
(0.12
)
Net loss per common share, discontinued operations
$
(0.21
)
Net loss per common share
$
(0.34
)